https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-07-06 13:08:012021-07-06 13:08:12Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-05-05 14:29:202021-05-05 14:29:20Vaccitech Announces Closing of $110.5 Million Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-04-30 08:08:562021-04-30 08:09:15Vaccitech Announces Pricing of Initial Public Offering
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-22 08:24:112021-03-22 08:24:48Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-18 08:21:572021-03-22 08:25:06Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-03-17 12:49:182021-03-17 12:49:18Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00ANevillhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngANevill2021-02-01 08:00:462021-02-01 09:14:55Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-12-30 14:13:122021-01-08 14:18:15Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-11-23 11:38:022020-12-01 11:38:36Oxford University breakthrough on global COVID-19 vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Katja Stouthttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngKatja Stout2020-10-20 10:21:252020-10-20 10:21:25Vaccitech expands management team with hires including CMO and CFO
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Other cookies
The following cookies are also needed - You can choose if you want to allow them:
